Genmab A/S
NASDAQ:GMAB

  • LAST PRICE
    23.4900
  • TODAY'S CHANGE (%)
    0.0900 (0.3846%)
  • Bid / Lots
    23.4000/ 1
  • Ask / Lots
    24.2000/ 4
  • Open / Previous Close
    23.3100 / 23.4000
  • Day Range
    23.2800
    23.5200
  • 52 Week Range
    23.2400
    35.8800
  • Volume
    604,712

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
GMAB
Genmab A/S
15.5B
19.0x
+22.71%
VCYT
Veracyte Inc
2.5B
-44.1x
---
CPRX
Catalyst Pharmaceuticals Inc
2.4B
37.5x
---
GLPG
Galapagos NV
1.9B
55.6x
---
BEAM
Beam Therapeutics Inc
1.9B
-13.3x
---
ARWR
Arrowhead Pharmaceuticals Inc
2.3B
-4.0x
---
As of 2024-10-05

Company Information

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact Information

Headquarters
Carl Jacobsens Vej 30VALBY, Denmark 2500
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Deirdre Connelly
President, Chief Executive Officer
Jan Van De Winkel
Independent Deputy Chairman of the Board
Pernille Erenbjerg
Chief Financial Officer, Executive Vice President
Anthony Pagano
Executive Vice President, Chief People Officer
Christopher Cozic

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$15.5B
Revenue (TTM)
$2.8B
Shares Outstanding
661.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.98
EPS
$1.24
Book Value
$7.12
P/E Ratio
19.0x
Price/Sales (TTM)
5.6
Price/Cash Flow (TTM)
---
Operating Margin
30.73%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.